Aratana Therapeutics (PETX) Tops Q2 EPS by 15c

Aratana Therapeutics (NASDAQ: PETX) reported Q2 EPS of ($0.23), $0.15 better than the analyst estimate of ($0.38).

"We continue to be on-track with our objective of having six products on the market in 2016 with a deep pipeline of additional therapeutics potentially coming to market behind those," stated Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics. "We are very excited about the outcomes we have achieved in our development programs."

For earnings history and earnings-related data on Aratana Therapeutics (PETX) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Sypris Solutions (SYPR) Reports Q2 Loss of $0.14
• Home Depot beats estimates, reaffirms fiscal 2026 guidance